Clinical findings
The follow-up period of the cases ranged from 3-108 months, and the mean follow-up period was 44.19 (±30.2) months. The mean preoperative PSA value of the cases was 7.8 (2.18-61) ng/ml (IQR:5.5-12.3). The mean postoperative PSA value was 0.07 ng/ml (IQR:0.03-0.25).
BCR was accepted as the patients having a PSA value of >0.2 ng/ml in two consecutive measurements in the postoperative period. The number of patients with BCR was 97 (34%). The mean preoperative PSA value of these patients was 14.6 ng/ml and the mean postoperative PSA value was 0.61 ng/ml. When these patients were evaluated in terms of RP GS, 17 (11.8%) of the patients in GG I, 33 (40.7%) in GG II, 20 (71.4%) in GG III, 11 (73.3%) in GG IV and 16 (94.1%) in GG V category had BCR. The relationship between RP GGs and BCR was statistically significant (p<0.001). As the GGs of the cases increased, the rate of BCR increased.
The mean time to BCR was calculated as 4 (IQR:3-18) months. It was found that 34 (35%) of the patients with BCR were treated with hormonotherapy, 57 (58.8%) with local radiotherapy, and 6 (6.2%) with chemotherapy. In the follow-up, while 256 (89.8%) of the patients were still alive, 29 (10.2%) died. In terms of the cause of death, the patients were divided into two groups as death due to prostate cancer (bone metastasis, radiotherapy/chemotherapy complications, etc.) and death from causes other than prostate cancer. There were 6 (2.1%) patients in the first group. The mean preoperative PSA values of these patients were 19.2 ng/ml. GSs were 3+5 in 3 and 4+5 in the other 3 patients. It was found that bone metastasis developed in all patients and related complications occurred. Postoperative follow-up time (from diagnosis to death) was 42 months on average. There were 23 (8.1%) patients who died from causes other than prostate cancer.